Market Overview

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced the FDA acceptance of the new drug application and European Medicines Agency validation of the marketing authorization for betrixaban for use in acute medically ill patients. With this news, the application’s probability of success has increased,” Credit Suisse’s Vamil Divan said in a report.

Divan maintains a Neutral rating on the company, while raising the price target from $20 to $29.

Increase In POS

Betrixaban now has a "fast track" status. The FDA has assigned priority review for the application, with an action date set for June 24, 2017.

Divan increased the probability of success assumption for the product from 40 percent to 65 percent, saying, “The general understanding the FDA must already have of the APEX study results and the support the drug seems to have both with officials at the FDA and with thought leaders in the community.”

A Pivotal Year Ahead

The betrixaban Prescription Drug User Fee Act date of June 24, 2017, is the most important catalyst in the list of “several important catalysts” Portola Pharma has over the next 12 months, the analyst commented.

The FDA will hold an Advisory Committee meeting to discuss the betrixaban application in Q2. Although this is based on a single Phase 3 study that almost missed the primary endpoint, “the totality of the data remains encouraging,” Johnson noted. He expects the company to resubmit their application for andexanet alfa, a novel anticoagulant, in Q2, with a potential approval by yearend 2017.

Latest Ratings for PTLA

May 2020Morgan StanleyMaintainsEqual-Weight
Apr 2020RBC CapitalInitiates Coverage OnOutperform
Jan 2020OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for PTLA
View the Latest Analyst Ratings


Related Articles (PTLA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration FDA Analyst Ratings Best of Benzinga

Latest Ratings

SWTXHC Wainwright & Co.Maintains124.0
ORBCRoth CapitalMaintains9.3
OPRXRoth CapitalMaintains85.0
CSPRRoth CapitalMaintains13.0
VVNTMorgan StanleyMaintains23.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at